$ZURA News

Wedbush Maintains Outperform on Zura Bio, Raises Price Target to $22

Guggenheim Maintains Buy on Zura Bio, Raises Price Target to $20

Zura Bio Q2 EPS $(0.21) Misses $(0.20) Estimate

William Blair Starts Zura Bio (ZURA) at Outperform

William Blair Initiates Coverage On Zura Bio with Outperform Rating

Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio’s Lead Therapy

Wedbush Reiterates Outperform on Zura Bio, Maintains $15 Price Target

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

Zura Bio Completes Enrollment In Phase 2 TibuSHIELD Trial of Tibulizumab in Adults With HS

Here's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Situation

ZURA BIO LTD (NASDAQ:ZURA) Q1 2026: Cash Runway Extended Through 2028 as Phase 2 Trials Advance

Zura Bio Q1 EPS $(0.22) Misses $(0.18) Estimate

Zura Bio Announces Separation From CFO Eric Hyllengren; Marlyn Mathew Named Principal Accounting And Principal Financial Officer

One Zura Bio Insider Raised Their Stake In The Previous Year

Zura Bio: Momentum Is Real, But TibuSHIELD Needs To Deliver

Zura Bio shares are trading lower after Oppenheimer lowered its price target on the stock from $16 to $15.

Zura Bio shares are trading lower after Oppenheimer lowered its price target on the stock from $16 to $15.

Oppenheimer Maintains Outperform on Zura Bio, Lowers Price Target to $15

Zura Bio Q4 EPS $(0.49) Misses $(0.22) Estimate

Zura Bio Says Design Of Its Ongoing Phase 2 TibuSURE Clinical Trial Evaluating Tibulizumab In SSc Accepted For Presentation At Systemic Sclerosis World Congress